Document:

Settlement Agreement

 Exhibit 10.52 
  
 SETTLEMENT AGREEMENT 
  

This Settlement Agreement is entered into by and between UNIGENE LABORATORIES, INC. (“Unigene”), a Delaware corporation, and COVINGTON &
BURLING (“Covington”), a Washington, D.C. partnership, who are the parties to Covington & Burling v. Unigene Laboratories, Inc., Civil Action No. 03-0005900, pending in the Superior Court of the District of Columbia. 

 
 WHEREAS, Covington has submitted statements to Unigene for legal services
performed for Unigene that remain unpaid in a total amount of $918,000; 
  
 WHEREAS, Unigene executed promissory notes for payment of a total of $800,000 of the unpaid amounts plus interest (the “Promissory Notes”) and has failed to make any payment of principal or interest on those Notes when due or
since due; 
  
 WHEREAS, Unigene’s total debt to Covington
(the “Total Debt”) is comprised of (i) $300,000 evidenced by that certain Promissory Note dated July 25, 2001, together with interest accrued thereon to the date of payment, (ii) $500,000 evidenced by that certain Promissory Note dated
October 10, 2001, together with interest accrued thereon to the date of payment, and (iii) $118,000, together with interest thereon accrued at the rate of six percent (6%) per annum commencing as of May 21, 2002 and continuing until the date of
payment (the “Additional Unpaid Fees”). As of December 14, 2003, the amount of the Total Debt to Covington is $1,098,270.35 (“Starting Total Debt”); and 
  
 WHEREAS, the parties have agreed to settle the pending lawsuit and resolve the dispute between them by the payments and
other terms set forth below; 
  
 NOW THEREFORE, in consideration
of the legal services performed for Unigene by Covington, the promises and releases set forth below, and other good and valuable consideration, the parties hereby agree as follows: 
  
 1. Until such time as the Total Debt to Covington has been discharged pursuant to Paragraph 2 below or paid in full,

  
 a. Unigene shall pay to Covington an amount equal to at least
$500,000 from each of the following milestone payments whenever received: (i) the milestone payment from Upsher-Smith Laboratories due and payable to Unigene upon the approval by the FDA of the New Drug Application for nasal calcitonin for the
treatment of osteoporosis, and (ii) the milestone payment from GlaxoSmithKline due and payable to Unigene upon the commencement of Phase I Clinical Trials for parathyroid hormones; 
  
 b. In addition to the payments required by Paragraph 1(a) hereof, Unigene shall pay to Covington ten percent (10%) of any
upfront payment, signing fee, milestone payment or similar payment (other than the milestone payments referred to in Paragraph 1(a)) received by Unigene from any licensee or distributor, including Upsher-Smith Laboratories and GlaxoSmithKline, at
any time after the date of this Agreement, such payment to be made within thirty (30) days of Unigene’s receipt of such funds. For purposes of this Agreement, a “similar payment” shall mean a lump sum payment which is not accompanied
by an obligation of Unigene to provide specified quantities of product or contract services in exchange for such payment, and an “upfront payment” shall not include a payment which is accompanied by such an obligation of Unigene.

  
 c. Unigene shall pay to Covington five percent (5%) of any
funds received by Unigene from any equity or debt financing or hybrid thereof that is completed at any time after the date of this Agreement, such payment to be made within thirty (30) days of Unigene’s receipt of such funds and without regard
to the terms and conditions of such financing; and 
  
 d. Unigene
shall pay to Covington two and one-half percent (2.5%) of all revenues received by Unigene regardless of source (other than the sources referred to in Paragraphs 1(a), (b), and (c)), as reported in its Form 10-Q filed with the SEC, during each
calendar quarter after December 31, 2004, such payment to be made within forty-five (45) days after the end of the quarter. 
  
 2. Any payment to Covington made by or on behalf of Unigene during a period specified below will discharge a dollar amount of the Starting Total Debt
equal to the amount of the payment multiplied by the factor corresponding to such period: 
  

			
	 On or before January 31, 2004
	  	1.4644
	 During February 2004
	  	1.4171
	 During March 2004
	  	1.3728
	 During April 2004
	  	1.33944
	 During May 2004
	  	1.30751
	 During June 2004
	  	1.2771
	 July 1 through September 30, 2004
	  	1.24805
	 October 1 through December 31,2004
	  	1.1938

 When any payment is made as provided in this Paragraph 2, the Starting Total Debt shall be reduced by the amount
discharged hereunder, such amount to be applied proportionately to principal and interest under the Promissory Notes and the Unpaid Fees as reflected in the Starting Total Debt. If at any time during 2004, the total of the amounts discharged
hereunder equals the amount of the Starting Total Debt, then the Total Debt shall be deemed paid in full and discharged and the Promissory Notes cancelled. 
  
 3. If the Total Debt has not been fully discharged by December 31, 2004 pursuant to Paragraph 2, or if Unigene has failed to comply with any of its
obligations under Paragraphs 1(a), (b), or (c) above, then Unigene shall be liable to pay to Covington the full dollar amount of the Total Debt, including all interest accrued to the date of payment, less any dollar amounts that have been discharged
pursuant to Paragraph 2. Any payment made after December 31, 2004 will be applied first to the Unpaid Fees until all the Unpaid Fees have been paid and thereafter to the latest-dated Promissory Note (in each case, with payment first applied to
accrued interest). 
  
 4. Unigene will enter into a paying agent
agreement (“the Agency Agreement”), substantially in the form attached hereto as Exhibit I, with the trust department of a bank acceptable to Covington (“the Bank”), whereby the Bank will undertake to receive milestone and other
similar payments due to Unigene and to promptly disburse to Covington the portion of each such payment due to Covington under Paragraphs 1(a) and (b) above. Covington will be a party to the Agency Agreement. Unigene shall instruct, in writing, those
third parties who have contractual obligations to make milestone and similar payments to Unigene to make such payments directly to the Bank. In the event that such third parties make such payments to Unigene, Unigene agrees to hold the portion
thereof due to be paid to Covington hereunder in trust solely for the benefit of Covington and shall promptly forward any such amount to Covington. The Agency Agreement shall remain in force until (a) the Total Debt has been discharged or paid in
full as provided in this Agreement or (b) all of the milestone payments specifically identified in Paragraphs 1(a) and (b) have been paid to the Bank. In the event that the paying agent under the Agency Agreement resigns while the Agency Agreement
is in force, Unigene shall enter into a paying agent agreement in accordance with this Paragraph with the trust department of another bank. Unigene will be solely responsible for the payment of fees to the Bank under the Agency Agreement and any
other expenses associated with the Agency Agreement. 
  
 5. On
even date herewith, Unigene shall enter into a security agreement, substantially in the form attached hereto as Exhibit II, granting to Covington a security interest in all of Unigene’s assets (exclusive of Unigene’s intellectual property
rights) and in the proceeds of its license agreements, junior only to the lien held by Tail Wind Fund Ltd., to secure the performance of Unigene’s obligations under this Agreement, such interest to continue in full force and effect until the
Total Debt has been discharged or paid in full as provided in this Agreement. 
  
 6. On even date herewith, Unigene, Jay Levy, Jean Levy, Warren Levy, and Ronald Levy shall enter into a subordination agreement, substantially in the form attached hereto as Exhibit III, with Covington, whereby the
security interests of the members of the Levy family in, or liens upon, Unigene’s assets will be subordinated to the security interest of Covington. Unigene will cooperate with Covington to record and perfect its security interest. Except as
otherwise permitted in said subordination agreement, Unigene shall not make any payments to any member of the Levy family in satisfaction of its indebtedness to them or any other extraordinary payments to any member of the Levy family, including
dividends and any increase in current compensation, until the Total Debt to Covington has been discharged or paid in full as provided in this Agreement. 
  
 7. This Agreement embodies the entire understanding of the parties and shall supercede all previous and contemporaneous communications, representations or
understandings, either oral or written, between the parties relating to the subject matter hereof except the Promissory Notes and the statements evidencing the Additional Unpaid Fees. 
  
 8. This Agreement will be submitted to the Court in Covington & Burling v. Unigene Laboratories, Inc. by the
parties for incorporation into a consent judgment. 
  
 9. Unigene
hereby releases, acquits and forever discharges Covington and its partners and employees from any and all obligations, claims, debts, promises or liabilities that Unigene ever had or has now or claims to have, arising out of the performance or
non-performance of any services for Unigene or arising from or in connection with Covington & Burling v. Unigene Laboratories, Inc. 
  
 10. Effective on the date when the Total Debt to Covington is discharged or paid in full as provided in this Agreement, Covington releases, acquits and
forever discharges Unigene and its officers, directors, stockholders, and employees from any and all obligations, claims, debts, promises, or liabilities that Covington ever had or has now or claims to have, arising out of any of the causes of
action asserted or that could have been asserted in Covington & Burling v. Unigene Laboratories, Inc., or arising out of or in connection with that suit. 
  
 11. It is understood and agreed that nothing in this Agreement or any of the releases given in this Agreement shall be
construed as an admission of liability on the part of either party. 
  
 12. Unigene represents and warrants that (i) the execution, delivery and performance of this Agreement by Unigene has been duly authorized by all requisite corporate action and does not and will not violate or conflict with any other
agreement to which Unigene is a party or is bound and (ii) this Agreement constitutes a valid and binding agreement of Unigene, enforceable against Unigene in accordance with its terms. 
  
 13. The person executing this Agreement on behalf of each party warrants and represents that he has full authority to
execute the Agreement and bind said party as a party to this Agreement. 
  
 14. This Agreement shall be binding in all respects upon all partners, successors, assigns and transferees of the parties. 
  
 15. This Agreement shall be construed according to the law of the District of Columbia. 

 IN WITNESS WHEREOF, the undersigned have signed this Agreement on December 18, 2003. 
  

			
	 UNIGENE LABORATORIES, INC

		
	 By:
	 	 Warren P. Levy

	 Name:
	 	 Warren P. Levy

	 Title:
	 	 President and CEO

	
	 COVINGTON & BURLING

		
	 By:
	 	 Russell H. Carpenter, Jr.

	 Name:
	 	 Russell H. Carpenter, Jr.

	 Title:
	 	 PartnerForm of Employment Agreement with Stephen M. Watters

 Exhibit 10.2 
  
 EMPLOYMENT AGREEMENT 
  

THIS EMPLOYMENT AGREEMENT, dated effective as of November 1, 2003 (the “Agreement”), is by and between Vertical Health Solutions,
Inc., a Florida corporation (the “Company”), and Stephen M. Watters (the “Employee”). 
  
 WHEREAS, the Company is a full-line custom-label manufacturer and distributor of nutritional supplements for veterinarians in the companion animal sector.

  
 WHEREAS, the Company wishes to assure itself of the services
of Employee for the period provided in this Agreement and Employee is willing to serve in the employ of the Company for such period upon the terms and conditions hereinafter set forth. 
  
 NOW THEREFORE, in consideration of the mutual covenants herein contained, the parties, intending to be legally bound, hereby
agree as follows: 
  
 1. EMPLOYMENT. The Company hereby agrees to
employ Employee upon the terms and conditions herein contained, and Employee hereby accepts such employment for the term described below. Employee agrees to serve as the Chief Executive Officer of the Company during the term of this Agreement and
shall report to the Company’s Board of Directors. In such capacity, Employee shall have such powers and responsibilities consistent with Employee’s position as the Chief Executive Officer. Throughout the term of this Agreement, Employee
shall devote Employee’s best efforts and substantially all of Employee’s business time and services to the business and affairs of the Company. 
  
 2. TERM OF AGREEMENT. The three (3) year initial term of the employment under this Agreement shall commence as of the date set forth above (the
“Effective Date”). After the expiration of such initial three-year period, the term of Employee’s employment hereunder shall automatically be extended without further action by the parties for successive one (1) year renewal
terms, provided that if either party gives the other party at least thirty (30) days advance written notice prior to the expiration of the then current term of such party’s intention to not renew this Agreement for an additional term, the
Agreement shall terminate upon the expiration of the current term. 
  
 3.
SALARY AND BONUS  
  
 a. Employee shall receive an annual base
salary during the the term of this Agreement of $165,000 payable in installments consistent with the Company’s normal payroll schedule; provided that the annual base salary shall be subject to periodic review and adjustment by the Compensation
Committee and/or the Board of Directors of the Company in its discretion. 
  
 b.
Employee shall also be eligible to participate in any executive bonus plan created by the Board of Directors in the same manner and to the same extent as the other executives of the Company in the discretion of the Board of Directors as set forth by
the Compensation Committee. 
  
 4. WELFARE AND FRINGE BENEFITS. 

  
 a. Life Insurance. The Company shall purchase a redeemable life
insurance policy on the life of Employee, 60% of the proceeds which shall be payable to Employee’s family and 40% to the Company. Upon either termination or non-renewal of employment, the Company will transfer ownership of policy to employee.

  
 b. Automobile and Other Allowances. During the term hereof, the Company
shall also provide Employee with an automobile allowance of up to $600.00 per month and shall pay the dues on behalf of Employee for one airline club membership per year. 

 c. Expenses. The Company shall reimburse Employee for all reasonable expenses he incurs in promoting the
Company’s business, including expenses for travel, entertainment of business associates, service and usage charges for business use of cellular phones and similar items, upon presentation by Employee from time to time of an itemized account of
such expenditures in a form acceptable to the Company. 
  
 d. Vacation.
Employee shall be entitled to an annual vacation of not less than four weeks, during which time his compensation shall be paid in full. 
  
 e. General. Employee shall be eligible to participate in such welfare benefit plans, programs, practices and policies of the Company as are generally applicable to
other employees. Without limiting the foregoing, Employee shall be entitled to such other benefits as the Board of Directors and/or the Compensation Committee of the Board of Directors may from time to time approve for him. 
  
 5. TERMINATION 
  
 a. Involuntary Termination. The Company may terminate Employee’s employment hereunder at any time by giving written notice to
Employee of termination. However, if Employee’s employment is terminated by the Company during the term of this Agreement pursuant to this Section 5(a), Employee shall be entitled to receive Employee’s base salary accrued
through the date of termination plus one additional year of base salary payable in the same manner as base salary was previously paid to Employee. 
  
 b. Disability. The Company shall be entitled to terminate Employee’s employment immediately if Employee becomes disabled (as defined below). Upon such
termination, the amount Employee shall be entitled to receive from the Company shall be limited to Employee’s base salary accrued through the date of termination and any payments as may be provided under any long-term disability plan or other
disability program or insurance policies maintained or provided by the Company. “Disabled” shall mean that for a period of three (3) consecutive months or an aggregate of four (4) months in any twelve (12) month period Employee is
incapable of fulfilling the duties of his or her position because of physical, mental or emotional incapacity, injury, sickness or disease. Any question as to the existence or extent of the disability upon which Employee and the Company cannot agree
shall be determined by a qualified, independent physician selected by the Company. The determination of any such physician shall be final and conclusive for all purposes. 
  
 c. Termination for Cause. The Company may terminate Employee’s employment hereunder for Cause (as defined below) immediately
without notice. If Employee’s employment is terminated by the Company for Cause, the amount Employee shall be entitled to receive from the Company shall be limited to Employee’s base salary accrued through the date of termination.

  
 For purposes of this Agreement, the term
“Cause” shall be limited to (i) embezzlement, fraud, misappropriation of corporate assets or a breach of the covenants set forth in Sections 9, 10 and 11 below; (ii) Employee being arrested or indicted in connection
with a felony; (iii) Employee being arrested or indicted of any lesser crime or offense committed in connection with the performance of Employee’s duties hereunder or involving moral turpitude; (iv) the habitual failure or refusal by Employee
to perform Employee’s duties hereunder after being provided with written warnings and a reasonable period to cure; or (v) chronic absenteeism. 
  
 d. Voluntary Termination by Employee. If Employee resigns or otherwise voluntarily terminates Employee’s employment before the end of the current term of this
Agreement, other than pursuant to the provisions of Section 5(e) of this Agreement, the amount Employee shall be entitled to receive from the Company shall be limited to Employee’s base salary accrued through the date of
termination. 

 e. Termination for Good Reason by Employee. Employee may terminate this Agreement for “Good Reason” (as
defined below), provided that he shall first provide the Company with prior written notice, which notice shall state with specificity the reason for the termination and provide the Company with thirty (30) days from and after the giving of such
notice to cure the breach. If the Company fails to cure the breach within such thirty days, Employee shall be entitled to receive Employee’s base salary accrued through the date of termination plus one additional year of base salary payable in
the same manner as base salary was previously paid to Employee. For purposes of Section 5(e), the Executive shall have “Good Reason” to terminate his employment hereunder if such termination shall be the result of:

  
 (i) any material demotion regarding Employee’s status, title,
authorities or responsibilities (including reporting responsibilities) under this Employment Agreement; or 
  
 (ii) the reassignment of Employee to a location more than thirty (30) miles from the location where he presently works. 
  
 6. DEATH. If Employee dies during the term of this Agreement, the Company shall pay to Employee’s estate a lump sum payment equal to the sum of
Employee’s base salary accrued through the date of death plus the total unpaid amount of any bonuses earned. In addition, the death benefits payable by reason of Employee’s death under any retirement, deferred compensation or other
employee benefit plan maintained by the Company shall be paid to the beneficiary designated by Employee in accordance with the terms of the applicable plan or plans. 
  
 7. CHANGE OF CONTROL.  
  
 a. Salary. Upon a Change in Corporate Control (as defined below), if there is a reduction in the Employee’s base salary, the Employee shall have the option to
terminate his Employment and should Employee elect to terminate his Employment, the Company shall be obligated to make a series of twelve (12) monthly payments to the Employee. Each monthly payment shall be equal to the sum of one-twelfth
(1/12th) of the Employee’s annual base salary, as in effect on the date of termination, provided that if the Employee obtains a replacement position with any new employer (including a position as an officer, employee,
consultant, or agent, or self-employment as a partner or sole proprietor), the payments shall be reduced by all amounts the Employee receives as compensation for services performed during such period. 
  
 b. Restricted Stock. Further, upon a Change in Corporate Control, the vesting of any
restricted stock granted to the Employee under the terms of the Company’s Employee Restricted Stock Plan shall become immediately vested in full and exercisable in full. 
  
 c. Definition. For purposes of this Agreement, a “Change in Corporate Control” shall include any of the following events:
i. The acquisition in one or more transactions of more than thirty percent (30%) of the Company’s outstanding Common Stock by any corporation, or other person or group (within the meaning of Section 14(d)(3) of the Securities Exchange Act of
1934, as amended). 
  

	 	i.	Any merger or consolidation of the Company into or with another corporation in which the Company is not the surviving entity, or any transfer or sale of substantially all of the
assets of the Company or any merger or consolidation of the Company into or with another corporation in which the Company is the surviving entity and, in connection with such merger or consolidation, all or part of the outstanding shares of Common
Stock shall be changed into or exchanged for other stock or securities of any other person, or cash, or any other property. 

  

	 	ii	Any person, or group of persons, announces a tender offer for at least thirty percent (30%) of the Company’s Common Stock. 

 d. Limitation. Notwithstanding anything else in this Agreement, the amount of severance compensation payable to
the Employee as a result of a Change in Corporate Control under this Section 7, or otherwise, shall be limited to the maximum amount the Company would be entitled to deduct pursuant to Section 280G of the Internal Revenue Code of 1986,
as amended. 
  
 8. WITHHOLDING. The Company shall, to the extent
permitted by law, have the right to withhold and deduct from any payment hereunder any federal, state or local taxes of any kind required by law to be withheld with respect to any such payment. 
  
 9. PROTECTION OF CONFIDENTIAL INFORMATION. Employee agrees that Employee shall
keep all confidential or proprietary information of the Company or relating to its business (including, but not limited to, information regarding the Company’s customers, vendors, pricing policies, methods of operation, proprietary computer
programs and trade secrets) confidential, and that Employee shall not (except with the Company’s prior written consent), while in the employ of the Company or thereafter, disclose any such confidential information to any person, firm,
corporation, association or other entity, other than in furtherance of Employee’s duties hereunder, and then only to those with a need to know. Employee shall not make use of any such confidential information for Employee’s own purposes or
for the benefit of any person, firm, corporation, association or other entity (except the Company) under any circumstances during or after the term of Employee’s employment. The foregoing shall not apply to any information which, is generally
disclosed to the public by the Company or is otherwise in the public domain at the time of disclosure. 
  
 Employee recognizes that because Employee’s work for the Company shall bring Employee into contact with confidential and proprietary information of
the Company, the restrictions of this Section 9 are required for the reasonable protection of the Company and its investments and for the Company’s reliance on and confidence in Employee. 
  
 Further, Employee agrees that upon request or upon termination of this
Agreement (for any reason), Employee shall deliver to the Company any and all drawings, notes, documents and other materials which he has received from the Company or which have originated from the employment activity. 
  
 10. COVENANT NOT TO COMPETE  
  
 a. Employee hereby agrees that Employee shall not, either during the employment term or
during a period of one (1) year from the time Employee’s employment under this Agreement ceases or is terminated (for whatever reason), engage in any business activities on behalf of any enterprise which competes with the Company. Employee
shall be deemed to be engaged in such competitive business activities if Employee participates in such a business enterprise as an employee, officer, director, consultant, agent, partner, proprietor, or other participant; provided that the ownership
of no more than 2 percent of the stock of a publicly traded corporation engaged in a competitive business shall not be deemed to be engaging in competitive business activities. 
  
 11. OWNERSHIP OF DEVELOPMENTS  
  
 a. All copyrights, patents, trade secrets, or other intellectual property rights associated with any ideas, concepts, techniques, inventions, processes, or works of
authorship develop or created by Employee during the course of performing work for the Company or its clients (collectively, the “Work Product”) shall belong exclusively to the Company and shall, to the extent possible, be
considered a work made by Employee for hire for the Company within the meaning of Title 17 of the United States Code. To the extent the Work Product may not be considered work made by Employee for hire for the Company, Employee agrees to assign and
automatically assigns to the Company at the time of creation of the Work Product, without any requirement of further consideration, any right, title, or interest Employee may have in such Work Product. Upon the request of the Company, Employee shall
take such further actions, including execution and delivery of instruments of conveyance, as may be appropriate to give full and proper effect to such assignment. 

 b. Solely for purposes of Sections 9, 10, 11 and 12 hereof only, the term “Company” also
shall include any existing or future subsidiaries of the Company that are operating during the time periods described herein and any other entities that directly or indirectly, through one or more intermediaries, control, are controlled by or are
under common control with the Company during the periods described herein. 
  
 12.
INJUNCTIVE RELIEF 
  
 a. Employee acknowledges and agrees that it
would be difficult to fully compensate the Company for damages resulting from the breach or threatened breach of the covenants set forth in Sections 9, 10 and 11 of this Agreement and accordingly agrees that the Company shall be
entitled to temporary and injunctive relief, including temporary restraining orders, preliminary injunctions and permanent injunctions, to enforce such provisions in any action or proceeding instituted in any court having subject matter
jurisdiction, without having to post a bond or other security. This provision with respect to injunctive relief shall not, however, diminish the Company’s right to claim and recover damages. Employee agrees to pay to the Company all costs and
expenses incurred by the Company relating to the enforcement of the terms of Sections 9, 10 and 11 hereof, including reasonable fees and disbursements of counsel (both at trial and appellate proceedings). 
  
 b. It is expressly understood and agreed that although the parties consider the restrictions
contained in this Agreement to be reasonable, if a court determines that the time or territory or any other restriction contained in this Agreement is an unenforceable restriction on the activities of Employee, no such provision of this Agreement
shall be rendered void but shall be deemed amended to apply as to such maximum time and territory and to such extent as such court may judicially determine or indicate to be reasonable. 
  
 c. Employee acknowledges and confirms that (a) the restrictive covenants contained in Sections 9 and 10 hereof are reasonably
necessary to protect the legitimate business interests of the Company, and (b) the restrictions contained in Sections 9 and 10 hereof (including without limitation the length of the term of the provisions of Sections 9 and
10 hereof) are not overbroad, overlong, or unfair and are not the result of overreaching, duress or coercion of any kind. Employee further acknowledges and confirms that Employee’s full, uninhabited and faithful observance of each of
the covenants contained in Sections 9 and 10 hereof shall not cause Employee any undue hardship, financial or otherwise, and that enforcement of each of the covenants contained herein shall not impair Employee’s ability to obtain
employment commensurate with Employee’s abilities and on terms fully acceptable to Employee or otherwise to obtain income required for the comfortable support of Employee and Employee’s family and the satisfaction of the needs of
Employee’s creditors. Employee acknowledges and confirms that Employee’s special knowledge of the business of the Company is such as would cause the Company serious injury or loss if Employee were to use such ability and knowledge to the
benefit of a competitor or were to compete with the Company in violation of the terms of Sections 9 and 10 hereof. Employee further acknowledges that the restrictions contained in Sections 9 and 10 hereof are intended to
be, and shall be, for the benefit of and shall be enforceable by, the Company’s successors and assigns. 
  
 d. If Employee shall be in violation of any provision of Sections 9 and 10, then each time limitation set forth in the applicable section shall be extended for a period of time equal to the period of
time during which such violation or violations occur. If the Company seeks injunctive relief from such violation in any court, then the time limitations shall be extended for a period of time equal to the pendency of such proceeding including all
appeals by Employee. 
  
 13. SEPARABILITY. If any provision of this
Agreement shall be declared to be invalid or unenforceable, in whole or in part, such invalidity or unenforceability shall not affect the remaining provisions hereof which shall remain in full force and effect. 

 14. ASSIGNMENT. This Agreement shall be binding upon and inure to the benefit of the heirs and
representatives of Employee and the assigns and successors of the Company, but neither this Agreement nor any rights hereunder shall be assignable or otherwise subject to hypothecation by Employee. 
  
 15. ENTIRE AGREEMENT. This Agreement represents the entire agreement of the
parties and shall supersede any and all previous contracts, arrangements or understandings between the Company and Employee. The Agreement may be amended at any time by mutual written agreement of the parties hereto. 
  
 16. GOVERNING LAW; VENUE. This Agreement shall be construed, interpreted, and
governed in accordance with the laws of the State of Florida, other than the conflict of laws provisions of such laws. Hillsborough or Pinellas County, Florida shall be the proper venues for any litigation arising out of this Agreement. 

 
 17. COUNTERPARTS. This Agreement may be executed in one or more counterparts
all of which taken together shall constitute one and the same instrument. 

 18. NOTICE. Any notice or other communication which is required or permitted under this Agreement shall be
in writing and shall be deemed to have been given, delivered, or made, as the case may be (notwithstanding lack of actual receipt by the addressee) (i) on the date sent if delivered personally or by cable, telecopy, telegram, telex, or facsimile
(which is confirmed), (ii) three (3) business days after having been deposited in the United States mail, certified or registered, return receipt requested, sufficient postage affixed and prepaid, or (iii) one (1) business day after having been
deposited with a nationally recognized overnight courier service (such as by way of example, but not limitation, U.S. Express Mail, Federal Express, or Airborne), to the parties at the following addresses (or at such other address for a party as
shall be specified by like notice): 
  

					
	If to the Company:	 	 Vertical Health Solutions, Inc.
 855 Dunbar
Avenue
 Oldsmar, FL 34677
 Attention:
President

		
	 	 	 Tel: (727) 548-8345
 Fax: (727)
548-7134

		
	With a copy to Counsel:	 	 Sichenzia, Friedman & Ross
 1065 Avenue
of the Americas
 New York, NY 10018
 Attention: Tom
Rose

	        If to the Employee:	 	  

  

  

	 	 	Fax	 	  

  
 IN WITNESS WHEREOF,
the Company has caused this Agreement to be duly executed, and the Employee has hereunto set Employee’s hand, as of the day and year first above written. 
  

			
	VERTICAL HEALTH SOLUTIONS, INC.
		
	By:	 	  

	 Name:
	 	Brian T. Nugent
	 Title:
	 	President and Director
	Date:	 	  

	
	EMPLOYEE:
		
	 	 	  

	 Name:
	 	Stephen M. Watters
	Date:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00064-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00064-of-00352.parquet"}]]